AtriCure (NASDAQ:ATRC) issued an update on its FY18 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of ($0.74)-($0.69) for the period, compared to the Thomson Reuters consensus estimate of ($0.80). The company issued revenue guidance of $198-201 million, compared to the consensus revenue estimate of $197.91 million.
ATRC stock traded down $1.19 during midday trading on Friday, reaching $31.35. 503,088 shares of the company’s stock traded hands, compared to its average volume of 386,068. The company has a debt-to-equity ratio of 0.32, a current ratio of 3.16 and a quick ratio of 2.37. AtriCure has a 52 week low of $14.88 and a 52 week high of $36.49. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -37.77 and a beta of 0.16.
AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, November 1st. The medical device company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). AtriCure had a negative net margin of 10.41% and a negative return on equity of 17.08%. The business had revenue of $49.90 million for the quarter, compared to the consensus estimate of $49.90 million. During the same period in the previous year, the firm earned ($0.22) EPS. The company’s revenue was up 18.2% compared to the same quarter last year. Equities research analysts anticipate that AtriCure will post -0.72 EPS for the current year.
ATRC has been the topic of several research analyst reports. Canaccord Genuity upped their price target on shares of AtriCure from $37.00 to $40.00 and gave the stock a buy rating in a report on Tuesday, October 9th. Needham & Company LLC upped their price target on shares of AtriCure from $36.00 to $39.00 and gave the stock a buy rating in a report on Thursday, October 4th. Zacks Investment Research raised shares of AtriCure from a sell rating to a hold rating in a report on Friday, August 24th. ValuEngine raised shares of AtriCure from a buy rating to a strong-buy rating in a report on Friday, August 3rd. Finally, BTIG Research reaffirmed a hold rating on shares of AtriCure in a report on Thursday, August 2nd. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $33.60.
In other news, SVP Justin J. Noznesky sold 4,000 shares of the company’s stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $30.32, for a total value of $121,280.00. Following the transaction, the senior vice president now owns 124,920 shares of the company’s stock, valued at $3,787,574.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 10.00% of the company’s stock.
AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.
Featured Story: What is a Stop Order?
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.